N/A
Manufactured by Ascend Laboratories, LLC
8,208 FDA adverse event reports analyzed
Last updated: 2026-04-15
FINGOLIMOD HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Ascend Laboratories, LLC. The most commonly reported adverse reactions for FINGOLIMOD HYDROCHLORIDE include MULTIPLE SCLEROSIS RELAPSE, LYMPHOPENIA, MULTIPLE SCLEROSIS, FATIGUE, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FINGOLIMOD HYDROCHLORIDE.
Out of 4,544 classified reports for FINGOLIMOD HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 8,208 FDA FAERS reports that mention FINGOLIMOD HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include MULTIPLE SCLEROSIS RELAPSE, LYMPHOPENIA, MULTIPLE SCLEROSIS, FATIGUE, DRUG INEFFECTIVE, HEADACHE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Ascend Laboratories, LLC in connection with FINGOLIMOD HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.